$-0.52
(Market cap
$10,022 Mln
Revenue (TTM)
$71 Mln
P/E Ratio
--
P/B Ratio
60.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-15.8
-
Debt to Equity
-6.5
-
Book Value
$--
-
EPS
$-7.2
-
Face value
--
-
Shares outstanding
139,023,418
10 Years Aggregate
CFO
$-1,144.29 Mln
EBITDA
$-1,391.98 Mln
Net Profit
$-1,754.13 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
| 11.6 | -8.1 | -3.8 | 100.6 | 25.3 | 16.5 | 21.0 |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
| 35.1 | -43.4 | 82.2 | 0.5 | 119.3 | 95.9 | 67.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
|
70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 |
| 82.6 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 258.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 365.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.2 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 588.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 352.6 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.4 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Cytokinetics Inc (CYTK)
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets... MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Read more
-
CEO, President, Principal Financial Officer & Director
Mr. Robert I. Blum
-
CEO, President, Principal Financial Officer & Director
Mr. Robert I. Blum
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cytokinetics Inc (CYTK)
What is the current share price of Cytokinetics Inc (CYTK) Today?
The share price of Cytokinetics Inc (CYTK) is $70.88 (NASDAQ) as of 02-Sep-2026 10:37 EDT. Cytokinetics Inc (CYTK) has given a return of 25.34% in the last 3 years.
What is the current PB & PE ratio of Cytokinetics Inc (CYTK)?
Since, TTM earnings of Cytokinetics Inc (CYTK) is negative, P/E ratio is not available.
The P/B ratio of Cytokinetics Inc (CYTK) is 60.31 times as on 28-Aug-2026, a 1064 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-9.91 |
-11.79 |
2024 |
-9.42 |
-41.03 |
2023 |
-15.72 |
-21.41 |
2022 |
-11.15 |
-40.21 |
2021 |
-17.80 |
15.72 |
What is the 52 Week High and Low of Cytokinetics Inc (CYTK)?
The 52-week high and low of Cytokinetics Inc (CYTK) are Rs 88.31 and Rs 44.91 as of 02-Sep-2026.
What is the market cap of Cytokinetics Inc (CYTK)?
Cytokinetics Inc (CYTK) has a market capitalisation of $ 10,022 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cytokinetics Inc (CYTK)?
Before investing in Cytokinetics Inc (CYTK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.